A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1+
SponsorMayo Clinic
About this trial
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
Eligibility criteria
Qualifiers
Followed by pediatric hematology/oncology
Receiving recombinant Erwinia asparaginase for treatment of malignancy
Disqualifiers
Patients < 1 year of age
Patients who have previously received recombinant Erwinia asparaginase within the past two weeks
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
10 Participants
are divided into 1 treatment groupLocations
1Mayo Clinic in Rochester55905, RochesterMinnesota, United States
Sponsors and collaborators
Mayo Clinic
Lead sponsor
Source ClinicalTrials.gov